Clearmind Medicine (CMND) announced the filing of a patent application in India covering next-generation psychedelic-based compounds for the treatment of mental health disorders and addiction. The patent application, filed with the Indian Patent Office, forms part of the company’s expanding global intellectual property portfolio and builds upon its exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. It protects novel new compounds designed to overcome the limitations of classical psychedelics, offering potentially safer, more effective, and scalable treatment options for underserved mental health conditions and addictive disorders.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: AtaiBeckley reports publication of BPL-003 study results
- Clearmind Medicine reports successful ongoing treatment in CMND-100 trial
- Clearmind Medicine granted six therapy patents in Hong Kong
- Clearmind Medicine announces Hong Kong patent filing for depression therapy
- Psychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort